Recent Updates
Recently added Catalysts
SIBN Positive Sentiment

SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023

Key Takeaway: SI-BONE, Inc. has announced that it will report its financial results for the second quarter of 2023 on August 7, 2023, after market close. A conference call will follow the announcement, allowing investors to engage with management. The company's leadership in the surgical treatment of musculoskeletal disorders has been established through extensive clinical evidence and successful procedures. This release sets the stage for stakeholders to assess the company's performance.
Price reaction · baseline $26.11 (2023-07-14 close) · 1 other SIBN headline(s) in the window, move may be shared
day 0 close · peak
+1.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE will report expected growth for Q2 2023 financial results
  • The company has supported over 3,000 surgeons in performing 80,000 procedures
  • Strong clinical evidence supports the efficacy of their technologies

Full Press Release Details

SANTA CLARA, Calif., July 17, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced it will report financial results for the second quarter of 2023 after market close on Monday, August 7, 2023. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the conference call may do so by registering at this link: https://edge.media-server.com/mmc/p/wguskxxw. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,000 surgeons in performing a total of over 80,000 sacropelvic procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 120 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.

Frequently Asked Questions

When will SI-BONE release its Q2 2023 financial results?

SI-BONE will announce its Q2 2023 financial results on August 7, 2023.

How can I listen to the SI-BONE conference call?

You can listen to the conference call by registering at the provided link.

How long will the SI-BONE webcast be available for replay?

The SI-BONE webcast will be available for replay for at least 90 days.

What has SI-BONE specialized in since 2009?

SI-BONE has specialized in minimally invasive SI joint surgery since 2009.

What evidence supports SI-BONE's technologies?

SI-BONE's technologies are supported by two randomized trials and over 120 publications.

Last updated: Jul 17, 2023